Provided by Tiger Trade Technology Pte. Ltd.

Immuneering Corp

4.61
-0.1700-3.56%
Pre-market: 4.680.0737+1.60%09:06 EDT
Volume:1.17M
Turnover:5.41M
Market Cap:297.67M
PE:-4.71
High:4.81
Open:4.74
Low:4.54
Close:4.78
52wk High:10.08
52wk Low:3.86
Shares:64.57M
Float Shares:49.21M
Volume Ratio:1.63
T/O Rate:2.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9796
EPS(LYR):-1.2729
ROE:-52.15%
ROA:-32.77%
PB:1.56
PE(LYR):-3.62

Loading ...

Immuneering Corporation Announces Grants of Inducement Awards

GlobeNewswire
·
Jul 18

Immuneering CFO Andrew Gengos Files Initial Beneficial Ownership Statement

Reuters
·
Jul 17

Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX), Vera Therapeutics (VERA) and Alnylam Pharma (ALNY)

TIPRANKS
·
Jul 13

Immuneering Initiated at Overweight by Cantor Fitzgerald

Dow Jones
·
Jul 08

Immuneering initiated with an Overweight at Cantor Fitzgerald

TIPRANKS
·
Jul 08

Kalaris Appoints Laurie Keating to Board, Replacing Morana Jovan-embiricos

Reuters
·
Jul 07

Top Executive Makes Bold Insider Move on Immuneering Stock

TIPRANKS
·
Jun 25

Immuneering CEO Benjamin Zeskind Acquires 2,400 Shares for $10,948.08

Reuters
·
Jun 25

Immuneering Chief Scientific Officer Brett Matthew Hall buys $25,045 of common shares

Reuters
·
Jun 17

Mizuho Securities Reaffirms Their Buy Rating on Immuneering (IMRX)

TIPRANKS
·
Jun 17

Immuneering Appoints Veteran Biotech Leader as New CFO

TIPRANKS
·
Jun 16

Immuneering Names Andrew Gengos as CFO

MT Newswires Live
·
Jun 15

Immuneering Names Andrew Gengos Chief Financial Officer

Dow Jones
·
Jun 15

Immuneering - Appoints Andrew Gengos as Chief Financial Officer Effective July 16, 2026

THOMSON REUTERS
·
Jun 15

Press Release: Immuneering Appoints Andrew Gengos as Chief Financial Officer

Dow Jones
·
Jun 15

Immuneering Shareholders Approve Directors and Auditor at Meeting

TIPRANKS
·
Jun 12

Immuneering's Phase 3 Trial of Atebimetinib Plus mGnP to Treat Pancreatic Cancer Doses First Patient

MT Newswires Live
·
Jun 11

Immuneering doses first patient in Phase 3 MAPKeeper 301 trial for first-line metastatic pancreatic cancer

Reuters
·
Jun 11

Immuneering - Topline Data From Phase 3 Trial Expected in Mid-2028

THOMSON REUTERS
·
Jun 11

Immuneering Buy Rating Reaffirmed as Analyst Sees ASCO Sell-Off as Overdone; $11 Price Target Maintained

TIPRANKS
·
Jun 02